Can 30,000 patients reveal Parkinson's hidden patterns?
NCT ID NCT04888364
This trial is taking on new participants right now.
First seen Aug 20, 2026 · Last updated Aug 21, 2026 · Updated 1 time
Summary
This study follows a large group of people with Parkinson's disease and related conditions in France to map how the disease unfolds over time. Researchers collect detailed information on symptoms, treatments, and genetic samples at regular visits. The goal is to identify distinct subtypes of the disease and factors that predict faster or slower progression, which could guide more personalized care in the future.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to better ways to predict how Parkinson's disease will progress and help tailor treatments to individual patients.
- What could go wrong
- This is an observational study, so it cannot prove what causes progression. Results may take years and might not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 30,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2021
- Expected to finish
-
Dec 2034
An estimate. End dates often move.
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
All patients followed at one expert center for PD or associated centers in France.
- Ages
-
10 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Diagnosis of Parkinson's disease according to UK PD brain bak criteria * OR diagnosis of parkinsonian syndrome: multiple system atrophy, progressive supranuclear palsy, dementia with Lewy body, or corticobasal syndrom * OR Subjects at risk of PD defined as : No symptom or diagnosis of Parkinson's disease nor parkinsonian syndrome, and relative to a patient with a diagosis of PD or parkinsonian syndrome, or carrier of a known mutation responsible for a genetic form of PD or patient with a diagnosis of idiopathic REEM sleep disorder or prodromal form of PD as defined by MDS criteria (Berg et al., 2015) AND for all participants * Affiliated to social security * Age \> 10 years Exclusion Criteria: * Subject under legal protection * Subject who do not consent to the research * for the optional skin biopsy only: clinically significant coagulation abnormalities or anticoagulant treatment
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORTICOBASAL SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre 01 Paris
RECRUITINGParis, 75013, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a synthetic peptide offer a new way to tackle Parkinson's?
- Could a home sleep test unlock better dementia care?
- Brain stimulation that adapts to sleep stages could restore rest in Parkinson's
- Can an antibody clear the toxic clumps behind a rare brain disease?
- Could a carbon fiber ankle brace help people with Parkinson's walk better?
- Planning ahead: could a simple program transform Parkinson's care?